StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
Titan Pharmaceuticals stock opened at $3.84 on Monday. The firm has a fifty day moving average of $3.58 and a 200-day moving average of $4.73. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- What is a Death Cross in Stocks?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- The 3 Best Retail Stocks to Shop for in August
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- Manufacturing Stocks Investing
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
